<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Ask the Expert: Successfully Developing PDX-Derived Organoid (PDXO) Models

q&a on how to successfully develop PDX-derived organoids pdxo

q&a on how to successfully develop PDX-derived organoids pdxoReview the key questions on the development of PDX-derived organoids (PDXO) from our recent webinar, answered by Dr. Rajendra Kumari, Global Head of Scientific Communication.

PDX-Derived Organoid Development

What are the Advantages of using Matrigel® for PDXO Culture?

Matrigel provides an extracellular matrix (ECM) to support stem cell growth, 3D aggregation, and polarization of stem cells, and also forms part of the protocols published by the Clevers lab. However, use of other synthetic hydrogels is described by other groups.

How do you Remove Normal Fibroblasts from the PDXO Culture?

The culture conditions propagate organoids of epithelial origin only, so do not support any stromal cells.

Is There any Scope that this Work could be Translated to Tumor Types that are Not Derived From Epithelial Cells?

Yes, we have attempted to establish organoid cultures of non-epithelial tumors e.g. brain, but these are still in the experimental phase. This is due to the conditions potentially differing from standard Hubrecht Organoid Technology (HUB) protocols, which are designed for epithelial organs rather than organoids derived from pluripotent stem cells.

What is the Average Number of Generations you've been able to Passage your Organoids?

This varies as it is dependent on the time it takes to develop a robust stable organoid line which may be achieved over 3 passages or more. Genetic stability is key here and we are still expanding this as we expand our PDXO biobanks.

What Assays would you use to Identify Organoids Compared to Spheroids?

The culture media is specifically designed to promote organoid development, however a pathologist typically examines our H&E images to confirm model identity and identify the multilineage structure of an organoid.

PDX-Derived Organoid Model Types

Have You had Success in Establishing PDXO from all Tumor Types?

Currently, we’ve generated organoids from our PDX models for over 13 different cancer types, and we’ve got many more in development.

Are Prostate Cancer Organoids Available?

We’ve generated a few prostate cancer PDX models, and one castrate-resistant prostate cancer model is currently growing as an organoid. It’s not ready for service yet, but hopefully will be in the near future.

Which Main Disease Subtypes do your Breast Cancer Models Represent, and How Many Models are There per Subtype?

We have a range of breast cancer subtypes within our PDX collection. For PDXO, we currently have two triple negative breast cancer (TNBC) organoids available and a further nine breast cancer PDXO coming through including TNBC and ER+ models.

Where Can We get a List of which Models you've Made into Organoids?

We’ve launched our new PDXO database, OrganoidBase. Here you’ll find all the information and data for the PDXO that we’ve established. More models and their data will be added in regular updates, as we have 100s more PDX-derived organoids in expansion and validation phases.

Since only the Most Aggressive Human Tumors grow as PDX, are your PDXOs Derived Exclusively from High Grade Cancer?

Typically, yes more aggressive tumors engraft better as PDX models. However, in our collection we have a range of different grade PDX and we will attempt to establish PDXO for all of them.

We’ll be publishing further PDXO Q&A posts to review correlating PDXO to PDX and patient tumors, and PDXO applications.

Related Posts